01. Gene therapy Boulikas.pdf - Gene therapy & Molecular Biology

Nakaya T, Iwai S, Fujinaga K, Sato Y, Otsuka E, Ikuta K (1997)
Decoy approach using RNA-DNA chimera oligonucleotides
to inhibit the regulatory function of human
immunodeficiency virus type 1 Rev protein. Antimicrob
Agents Chemother 41, 319-325.
Naviaux RK and Verma IM (1992) Retroviral vectors for
persistent expression in vivo. Curr Opin Biotechnol 3, 540-
547.
Neri D, Carnemolla B, Nissim A, Leprini A, Querze G, Balza E,
Pini A, Tarli L, Halin C, Neri P, Zardi L, Winter G (1997)
Targeting by affinity-matured recombinant antibody
fragments of an angiogenesis associated fibronectin isoform.
Nat Biotechnol 15, 1271-1275.
Nevins JR (1992) E2F: a link between the RB tumor suppressor
protein and viral oncoproteins. Science 258, 424-429.
Newman KD, Dunn PF, Owens JW, Schulick AH, Virmani R,
Sukhova G, Libby P, Dichek DA (1995) Adenovirusmediated
gene transfer into normal rabbit arteries results in
prolonged vascular cell activation, inflammation, and
neointimal hyperplasia. J Clin Invest 96, 2955-2965.
Nguyen DM, Wiehle SA, Koch PE, Branch C, Yen N, Roth JA,
Cristiano RJ (1997b) Delivery of the p53 tumor suppressor
gene into lung cancer cells by an adenovirus/DNA complex.
Cancer Gene Ther 4, 191-198.
Nguyen DM, Wiehle SA, Roth JA, Cristiano RJ (1997a) Gene
delivery into malignant cells in vivo by a conjugated
adenovirus/DNA complex. Cancer Gene Ther 4, 183-190.
Nickels JT and Broach JR (1996) A ceramide-activated protein
phosphatase mediates ceramide-induced G1 arrest of
Saccharomyces cerevisiae. Genes Dev 10, 382-394.
Nielsen LL, Dell J, Maxwell E, Armstrong L, Maneval D, Catino
JJ (1997) Efficacy of p53 adenovirus-mediated gene therapy
against human breast cancer xenografts. Cancer Gene Ther
4, 129-138.
Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R,
Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P,
Glover T, Collins FS, Weston A, Modali R, Harris CC,
Vogelstein B (1989) Mutations in the p53 gene occur in
diverse human tumour types. Nature 342, 705-708.
Nilson BH, Morling FJ, Cosset FL, Russell SJ (1996) Targeting
of retroviral vectors through protease-substrate interactions.
Gene Ther 3, 280-286.
Norrby K (1997) Angiogenesis: new aspects relating to its
initiation and control. APMIS 105, 417-437
Nowak R (1995) Entering the postgenome era. Science 270, 368-
371.
Nussbaum RL and Polymeropoulos MH (1997) Genetics of
Parkinson's disease. Hum Mol Genet 6, 1687-1691.
O'Neill, E.A. Fletcher, C., Burrow, C.R., Heintz, N., Roeder,
R.G., Kelly, T.J. (1988) Transcription factor OTF-1 is
functionally identical to the DNA replication factor NF-III.
Science 241, 1210-1213.
O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS,
Flynn E, Birkhead JR, Olsen BR, Folkman J (1997)
Endostatin: an endogenous inhibitor of angiogenesis and
tumor growth. Cell 88, 277-285.
Gene Therapy and Molecular Biology Vol 1, page 151
151
O'Reilly MS, Holmgren L, Chen C, Folkman J (1996)
Angiostatin induces and sustains dormancy of human
primary tumors in mice. Nat Med 2, 689-692.
O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA,
Moses M, Lane WS, Cao Y, Sage EH, Folkman J (1994)
Angiostatin: A novel angiogenesis inhibitor that mediates the
suppression of metastases by a Lewis lung carcinoma. Cell
79, 315-328.
Ohno T, Gordon D, San H, Pompili VJ, Imperiale MJ, Nabel GJ,
and Nabel EG (1994) Gene therapy for vascular smooth
muscle cell proliferation after areterial injutry. Science 265,
781-784.
Ohno T, Yang Z, Ling X, Jaffe M, Nabel EG, Normolle D, Nabel
GJ (1997) Combination gene transfer to potentiate tumor
regression. Gene Ther 4, 361-366.
Okada H, Miyamura K, Itoh T, Hagiwara M, Wakabayashi T,
Mizuno M, Colosi P, Kurtzman G, Yoshida J (1996) Gene
therapy against an experimental glioma using adenoassociated
virus vectors. Gene Ther 3, 957-964.
Okamoto K and Beach D (1994) Cyclin G is a transcriptional
target of the p53 tumor suppressor protein. EMBO J 13,
4816-4822.
Okamoto T, Kaneda Y, Yuzuki D, Huang SKS, Chi DDJ, and
Hoon DSB (1997) Induction of antibody response to human
tumor antigens by gene therapy using a fusigenic viral
liposome vaccine. Gene Ther 4, 969-976.
Okuyama Y, Sowa Y, Fujita T, Mizuno T, Nomura H, Nikaido
T, Endo T, Sakai T (1996) ATF site of human RB gene
promoter is a responsive element of myogenic
differentiation. FEBS Lett 397, 219-224.
Oliner JD Kinzler KW, Meltzer PS, George DL, Vogelstein B
(1992) Amplification of a gene encoding a p53-associated
protein in human sarcomas. Nature 358, 80-83.
Olsen JC, Sechelski J (1995) Use of sodium butyrate to enhance
production of retroviral vectors expressing CFTR cDNA.
Hum Gene Ther 6, 1195-1202.
Ono T, Fujino Y, Tsuchiya T, Usuda M (1990) Plasmid DNAs
directly injected into mouse brain with lipofectin can be
incorporated and expressed by brain cells. Neurosci Lett
117, 259-263.
Ory DS, Neugeboren BA, Mulligan RC (1996) A stable humanderived
packaging cell line for production of high titer
retrovirus/vesicular stomatitis virus G pseudotypes. Proc
Natl Acad Sci USA 93, 11400-11406.
Osaki T, Tanio Y, Tachibana I, Hosoe S, Kumagai T, Kawase I,
Oikawa S, Kishimoto T (1994) Gene therapy for
carcinoembryonic antigen-producing human lung cancer
cells by cell type-specific expression of herpes simplex virus
thymidine kinase gene. Cancer Res 54, 5258-5261.
Otani K, Nita I, Macaulay W, Georgescu HI, Robbins PD, Evans
CH (1996) Suppression of antigen-induced arthritis in rabbits
by ex vivo gene therapy. J Immunol 156, 3558-3562.
Pages J-C, Andreoletti M, Bennoun M, Vons C, Elcheroth J,
Lehn P, Houssin D, Chapman J, Briand P, Benarous R,
Franco D, Weber A (1995) Efficient retroviral-mediated
gene transfer into primary culture of murine and human